[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350313-105":59,"doc-detail-350313-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","emerging-insights-of-management-of-venous-thromboembolism-in-patients-with-cancer-review","Emerging Insights of Management of Venous Thromboembolism in Patients With Cancer - Review","","Cancer-associated thrombosis (CAT), especially venous thromboembolism (VTE), drives substantial mortality in people with cancer and remains a leading cause of death beyond tumor progression. Elevated VTE risk arises from hypercoagulable biology and cancer therapies, with advanced malignancies facing the greatest threat. Effective management depends on primary thromboprophylaxis and anticoagulation, while recurrent VTE and differing bleeding risks across cancer types complicate treatment duration and drug choice. Low-molecular-weight heparin and direct oral anticoagulants are reviewed alongside evidence-based guideline gaps.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/emerging-insights-of-management-of-venous-thromboembolism-in-patients-with-cancer-review/350313/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/emerging-insights-of-management-of-venous-thromboembolism-in-patients-with-cancer-review/350313.png","ImageObject",300,407,{"name":92,"@type":93},"Terk","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is venous thromboembolism a major concern in cancer patients?","Question",{"text":112,"@type":113},"VTE is strongly linked to increased mortality and adverse outcomes in cancer. Cancer patients have a substantially higher VTE incidence than the general population, and VTE can even be the first sign of occult malignancy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What are the key management challenges addressed in this review?",{"text":117,"@type":113},"The main challenge is balancing thromboprophylaxis and treatment effectiveness against anticoagulant-related bleeding risk. Additional complexity comes from different thrombotic and bleeding risks across cancer types and from recurrent VTE affecting anticoagulation duration.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the review compare low-molecular-weight heparin and direct oral anticoagulants?",{"text":121,"@type":113},"Low-molecular-weight heparin largely replaced warfarin, but direct oral anticoagulants are discussed as a competing option with demonstrated efficacy. The review highlights how clinical scenarios and evidence influence anticoagulant selection.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350313,1790646209,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},1099525198933,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","| Emerging Insights of Management of Venous Thromboembolism in Patients With Cancer\u003Cbr>Zidong Guan1 , Xiaotong Li1 , and Xiaogang Zhu2 | Clinical and Applied Thrombosis/Hemostasis Volume 32: 1–20 © The Author(s) 2026 Article reuse guidelines:\u003Cbr>[sagepub.com/journals-permissions](sagepub.com/journals-permissions)\u003Cbr>[DOI: 10.1177/10760296261454788](DOI: 10.1177/10760296261454788)\u003Cbr>[journals.sagepub.com/home/cat](journals.sagepub.com/home/cat)\u003Cbr>\u003Cbr>|\n| --- | --- |\n| Abstract\u003Cbr>Cancer-associated thrombosis (CAT), particularly venous thromboembolism (VTE), is a major contributor to mortality in cancer patients and is widely recognized as a leading cause of death after the direct effects of cancer progression. Cancer patients have significantly higher VTE risk than the general population, due to hypercoagulable states and anticancer therapies, with those with advanced malignancies carrying the highest risk. Primary thromboprophylaxis and anticoagulation are pivotal for CAT management. Despite advances, key challenges include different thrombotic and bleeding risks across cancers and how recurrent VTE affects anticoagulation duration. Low-molecular-weight heparin (LMWH) has largely replaced warfarin, and direct oral anticoagulants (DOACs) are challenging LMWH’s first-line role with proven efficacy. However, the key dilemma is balancing thromboprophylaxis and treatment against anticoagulant-induced bleeding, particularly in the context of recurrent VTE. Current CAT guidelines show discrepancies and gaps in clinical coverage; some conclusions derived from meta-analyses need validation via more randomized controlled trials. This review synthesizes recent CAT research (focused on VTE) across epidemiology, pathophysiology, laboratory assessments, and management. It analyzes how cancer type, patient conditions, and drug-drug interactions influence anticoagulant selection, supported by areview of the corresponding experimental evidence. Additionally, the article addresses key clinical scenarios (e.g., intracerebral hemorrhage, pregnancy, pediatric and adolescent patients, and COVID-19) to aid clinical decision-making, delineates unresolved clinical controversies, and integrates high-quality cohort/subgroup data to guide meta-analysis validation. By summarizing risk-benefit consideration, this article provides a framework for complex cases and informs future RCT design.\u003Cbr>Keywords\u003Cbr>cancer-associated thrombosis, venous thromboembolism, virchow’s triad, anticoagulation, direct oral anticoagulants, hemorrhagic risk\u003Cbr>Received: 8 October 2025; Revised: 18 February 2026; Accepted: 13 May 2026\u003Cbr>1. Introduction\u003Cbr>Cancer remains a major global health burden and one of the leading causes of mortality, with an estimated 20 million new cases and 9.7 million deaths reported worldwide in 2022.1 Beyond direct invasion and metastasis, cancer can induce systemic complications, among which venous thromboembolism (VTE) carries a high mortality rate (second only to cancer progression) and profoundly influence prognosis and therapy.2 Cancer patients are at a markedly increased risk of VTE, with incidence rates up to nine times higher than in the general population.3 Moreover, approximately one-fifth of patients |  |\n| 1Fu Xing Hospital, Capital Medical University, Beijing, China\u003Cbr>2Department of Cardiology, Fu Xing Hospital, Capital Medical University, Beijing, China\u003Cbr>Corresponding author:\u003Cbr>Xiaogang Zhu, Department of Cardiology, Fu Xing Hospital, Capital Medical University, No. 20 Fuxingmenwai Street, Xicheng District, Beijing 100038, China.\u003Cbr>Email: [shougun@126.com](shougun@126.com) |  |\n\nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons  \nAttribution-NonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use, reproduction and distribution of the work without further permission pr","cbCaitqpLJSs40WN","https://ap.wps.com/l/cbCaitqpLJSs40WN","pdf",2672882,"English","# Abstract\n# 1. Introduction\n## Cancer-associated thrombosis (CAT) and VTE burden\n# 2. Epidemiology","[{\"question\":\"Why is venous thromboembolism a major concern in cancer patients?\",\"answer\":\"VTE is strongly linked to increased mortality and adverse outcomes in cancer. Cancer patients have a substantially higher VTE incidence than the general population, and VTE can even be the first sign of occult malignancy.\"},{\"question\":\"What are the key management challenges addressed in this review?\",\"answer\":\"The main challenge is balancing thromboprophylaxis and treatment effectiveness against anticoagulant-related bleeding risk. Additional complexity comes from different thrombotic and bleeding risks across cancer types and from recurrent VTE affecting anticoagulation duration.\"},{\"question\":\"How does the review compare low-molecular-weight heparin and direct oral anticoagulants?\",\"answer\":\"Low-molecular-weight heparin largely replaced warfarin, but direct oral anticoagulants are discussed as a competing option with demonstrated efficacy. The review highlights how clinical scenarios and evidence influence anticoagulant selection.\"}]","Emerging Insights of Management of Venous Thromboembolism in Patients With Cancer - Review | PDF",1790088396,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a2b06c5f568148ccb65a65660f1ecde3.webp",983,1310,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/28104a51ad68f87980b55edb34dcc722.webp",982,1309,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7580038d5b90c676bbcdd55194926cbb.webp",981,1308,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7cd45e094d6c7972e90256cdf691504b.webp",980,1306]